Russia approved Selank for anxiety in 2009. Western regulatory agencies have not — and the gap between those two facts defines the entire evidence landscape for this compound.
Russia approved Selank for generalized anxiety disorder (GAD) in 2009 based on trials that compared it favorably with medazepam, a benzodiazepine. Those trials aren't indexed in PubMed and don't meet modern Western standards. The Western evidence is thinner: one fMRI study in 52 adults showing real brain effects, plus rodent data with anxiety-like reductions of 39.6% in a 2022 morphine-withdrawal model. No Western Phase III exists in any indication.
Selank sits in an unusual middle ground. It has real regulatory approval for a real condition. It also has clinical trials that Western reviewers cannot fully evaluate, because they are in Russian and predate modern trial registration. The sections below summarize what the published literature shows, where it falls short, and how to interpret the gap.
Most research peptides in the literature are either FDA-approved (tesamorelin, bremelanotide) or lack approval anywhere. Selank is the rare case of foreign regulatory approval without Western replication — a distinction that warrants careful reading of the evidence base rather than either wholesale acceptance or dismissal.
What's behind the Russian approval?
Selank's 2009 approval rests on Russian-language trials going back to the 1990s. The development team worked at the V.V. Zakusov Research Institute of Pharmacology and the Institute of Molecular Genetics. They reported that Selank matched medazepam (a benzodiazepine) for anxiety reduction, with none of the sedation, motor side effects, or withdrawal that benzodiazepines bring.
Medazepam is not widely used in the U.S. It is a benzodiazepine used in Russian clinical practice comparably to how Western clinicians use diazepam or lorazepam. The Russian characterization of Selank — comparable anxiolytic efficacy, improved safety profile, no abuse liability — represents the core regulatory claim. That claim rests on the Russian-language trial dataset, not on PubMed-indexed evidence.
Where this falls short: the Russian trials have four problems by Western standards. They're not in PubMed. They predate trial registration. Their blinding and randomization weren't held to modern Phase III rigor. And the investigators are the same group who invented the molecule — a classic conflict-of-interest pattern the Russian-school peptide literature shares with other small national research traditions.
None of this invalidates the Russian work. It means the dataset cannot be treated as equivalent to a Western Phase III. The Russian data supports the Russian prescribing context. It does not, on its own, establish an evidentiary basis for Western clinical adoption.
What does the rodent anxiety data show?
The strongest modern animal evidence comes from Konstantinopolsky's 2022 morphine-withdrawal study in Bulletin of Experimental Biology and Medicine. Withdrawing morphine from rats causes anxiety-like behavior: tremor, posture changes, hypersensitivity. The team measured whether Selank could blunt it.
One intraperitoneal dose of Selank at 0.3 mg/kg produced three measurable effects:
- Total withdrawal score dropped by 39.6%.
- Convulsions and posture problems eased.
- Tactile sensitivity threshold rose 9-fold, meaning the rats stopped flinching at small stimuli.
The comparison group received diazepam (Valium) at 2 mg/kg. Diazepam did slightly better. But Selank closed most of the gap at a much lower dose, without sedation or the abuse pattern that comes with benzodiazepines.
Selank at 0.3 mg/kg produced anxiolytic-like effects in a rodent morphine-withdrawal paradigm with magnitude slightly inferior to diazepam at 2 mg/kg.
— Konstantinopolsky et al., Bulletin of Experimental Biology and Medicine, 2022
Where this falls short: rodent anxiety tests have a poor track record of predicting human anxiolytic effects. Numerous compounds have demonstrated efficacy in elevated-plus-maze paradigms and failed in clinical trials in GAD research subjects. The morphine-withdrawal model has face validity but is not the gold-standard preclinical anxiety paradigm. The signal is real; translational relevance to human GAD remains unconfirmed.
What about the inflammation data?
The Yasenyavskaya 2021 study in Current Reviews in Clinical and Experimental Pharmacology examined a different mechanistic angle: cytokines. Cytokines are immune-signaling proteins, and chronic stress has been shown to elevate specific pro-inflammatory markers (IL-6, TNF-alpha) in animal and human stress models. That inflammatory pattern has been observed in research subjects with treatment-resistant depression and anxiety who do not respond to standard SSRIs.
The team stressed rats socially for 20 days while dosing Selank at 100 µg/kg/day. The result:
- Stress-driven spikes in IL-1β, IL-6, TNF-α, and TGF-β1 dropped.
- IL-4 (an anti-inflammatory cytokine that stress had suppressed) recovered.
- Effects appeared stress-dependent, not constitutive — Selank seems to normalize, not blanket-suppress.
If this translates to humans, the inflammation-driven anxiety phenotype — subjects with autoimmune comorbidity, post-infectious anxiety, or chronic-stress overlap — may represent the most mechanistically relevant population. That hypothesis has not been tested in a clinical trial.
What about the brain-imaging study?
The Panikratova 2020 study in Doklady Biological Sciences is the best Western-quality human study of Selank we have. The team scanned 52 healthy adults with fMRI before, 5 minutes after, and 20 minutes after a single intranasal dose. The design compared Selank, Semax, and placebo.
The finding: Selank shifted functional connectivity between the right amygdala and several temporal-cortex regions. These areas are implicated in threat detection, emotional processing, and face recognition — the network that preclinical anxiolytic research hypothesizes as a target for this compound class.
This is real evidence of brain engagement. It isn't proof of anxiety reduction. A healthy adult's brain lighting up on fMRI doesn't predict whether a person with GAD will feel better. But it's a real biological footprint, which is more than most grey-market peptides can show.
Selank
The same Russian-school anxiolytic peptide cited across the trial-readout literature in this article. Lab-verified identity and purity.
What do the gut and stress-hormone studies add?
The Mukhina 2020 study in Bulletin of Experimental Biology and Medicine looked beyond the brain. Researchers immobilized rats (a standard chronic-stress model) while dosing Selank at 80, 250, or 750 µg/kg. Three effects landed:
- Corticosterone (the rat version of cortisol) rose less under stress.
- Colon-wall damage from stress eased.
- Rats adapted to the restraint paradigm faster.
The corticosterone finding is mechanistically notable: corticosterone (the rodent equivalent of cortisol) is a primary HPA-axis stress mediator. The Mukhina data suggest Selank attenuated corticosterone elevation specifically under stress conditions, rather than producing a constitutive suppression analogous to benzodiazepine-class CNS depression. The proposed mechanism — stress-state engagement rather than baseline CNS inhibition — has not been confirmed in a human HPA-axis study.
The colon finding matters for a different reason. Stress drives IBS flares, functional dyspepsia, and stress colitis. If Selank protects the gut wall in rats, that's broader stress-protection than a pure anxiolytic would deliver. None of this is GAD trial data. It's a coherent mechanistic story that hasn't been tested in a Phase III.
How does Selank compare to standard anxiety drugs?
The published evidence base for standard GAD treatments provides a useful reference frame.
- SSRIs and SNRIs (escitalopram, sertraline, venlafaxine, duloxetine) have decades of Phase III data for GAD, with onset of 2–4 weeks and documented rates of sexual side effects and discontinuation syndromes. These agents are established first-line options in clinical guidelines.
- Cognitive behavioral therapy (CBT) has the strongest evidence base of any GAD intervention, with durable outcomes reported in long-term follow-up studies.
- Benzodiazepines show rapid onset in clinical trials but are associated with dependence, withdrawal, and cognitive effects. Clinical guideline use is generally limited to acute contexts.
- Buspirone is a non-benzodiazepine anxiolytic characterized in the literature as non-sedating with low abuse liability — the closest approved comparator to Selank's proposed pharmacological profile.
If the Russian clinical data hold up under Western replication, Selank's proposed profile — non-sedating, no withdrawal, neuro-immune mechanism — would represent a distinct niche between buspirone and benzodiazepines. No Western Phase III has been conducted to test that hypothesis.
What's the safety profile?
Russian clinical use characterizes Selank as well tolerated at short-course nasal-drop dosing. The most-reported issue is mild nasal irritation. No withdrawal syndrome, no abuse pattern, no meaningful sedation at therapeutic doses.
The Western data doesn't contradict this but doesn't independently confirm it either. The Panikratova 2020 fMRI study in 52 adults reported no notable adverse events. Rodent studies show no obvious toxicity at clinically relevant doses. That's not the same as the millions of patient-years of post-marketing safety data behind an FDA-approved drug.
Where this falls short: Russian approved use is short-course — days to weeks, not chronic. Long-term safety is essentially unstudied. Drug interactions with GABA-active drugs (alcohol, benzos, barbiturates), antidepressants, or other neuroactive meds are theoretically concerning but uncharacterized. And grey-market product quality varies wildly — the Russian pharmaceutical-grade nasal drops and the U.S. research-peptide vial may not be chemically identical.
Selank
Tuftsin analog · 7 aa, N-acetylated. The same reference compound used across the cited preclinical studies. COA available with each lot.
Open questions in the Selank literature
The published evidence base for Selank leaves several questions unresolved. These represent the gaps researchers and clinicians reviewing the literature would need to address before Selank could be evaluated as a Western clinical candidate:
- Western replication of the Russian trials. The 2020 Panikratova fMRI study and the 2022 Konstantinopolsky withdrawal paper represent the strongest PubMed-indexed data. The core Russian GAD trials remain outside Western peer-review norms.
- Methodological equivalence assessment. Researchers comparing the Russian Phase II dataset with a Western Phase III standard must account for differences in blinding, randomization, trial registration, and conflict-of-interest management.
- Phenotypic specificity. Whether the cytokine-modulation data (Yasenyavskaya 2021) identifies an inflammation-driven anxiety subpopulation that would show enhanced response has not been tested in a clinical trial.
- Product identity across manufacturing contexts. Russian pharmaceutical-grade nasal-drop formulations and research-grade lyophilized peptide preparations may differ in purity, excipients, and bioavailability; these have not been formally compared.
- Drug interaction characterization. Interactions with GABA-active compounds, antidepressants, and other neuroactive agents are theoretically plausible but uncharacterized in the published literature.
- Chronic-use safety. The Russian approved indication is short-course; long-term safety data beyond the acute study windows have not been published.
What to know now
- Russian regulatory status: approved since 2009 for generalized anxiety disorder; not FDA/EMA-approved.
- Russian clinical comparison: characterized as comparable to medazepam (a benzodiazepine) without sedation, motor impairment, or abuse liability.
- Best Western preclinical anxiolysis data: Konstantinopolsky 2022, 0.3 mg/kg single-dose IP reduced morphine-withdrawal index by 39.6% in rats, effects slightly inferior to diazepam at 2 mg/kg.
- Cytokine modulation: Yasenyavskaya 2021, 100 µg/kg/day for 20 days reduced stress-induced IL-1β, IL-6, TNF-α, TGF-β1 elevations, restored IL-4 (chronic social stress model).
- Best Western human study: Panikratova 2020, n=52 healthy adults, intranasal Selank produced right amygdala connectivity modulation within 20 minutes.
- HPA / gut effects: Mukhina 2020, Selank reduced corticosterone elevation and protected colon morphology under restraint stress in rats.
- Western RCT gap: no PubMed-indexed randomized clinical trial in GAD or any indication, 2020–2026.
- Mechanism hypothesis: if inflammation-associated anxiety is a distinct phenotype, Selank's neuro-immune profile may be specifically relevant — but this has not been tested in a clinical trial.
What we're watching
Three things over the next 18 months. First, whether any Western academic group registers a Phase II of Selank, most likely in an inflammation-driven anxiety subpopulation where the cytokine mechanism is relevant. Second, whether the broader anxiolytic pipeline shifts toward neuro-immune mechanisms, which would pull Selank into Western research interest. Third, whether non-Russian labs replicate the IL-6 and TNF-alpha findings in models beyond social stress — replication is what would move Selank from "interesting Russian biology" to "credible Western candidate."
References
- Konstantinopolsky, M. A., Chernyakova, I. V., & Kolik, L. G. (2022). Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bulletin of Experimental Biology and Medicine, 173(6), 730–733. https://doi.org/10.1007/s10517-022-05624-x
- Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., et al. (2021). The influence of Selank on the level of cytokines under the conditions of "social" stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162–167. https://doi.org/10.2174/1574884715666200704152810
- Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., et al. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
- Mukhina, A. Y., Mishina, E. S., Bobyntsev, I. I., et al. (2020). Morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with Selank. Bulletin of Experimental Biology and Medicine, 169(2), 281–285. https://doi.org/10.1007/s10517-020-04868-9